Replies to post #195 on TScan Therapeutics Inc (TCRX)

[jondoeuk]

Is this the most promising TCR-T bio?

Yes, that's public.

TCR-T Multiplexing CTAs seems more effective than neoantigen ACT?

We will have to wait for the data, but I don't see why doing that (as well as the other modifications) shouldn't increase the depth and duration of response over the current single-targeted approach. I think one of the reasons targeting neoantigens has fallen short is due in part to the prediction algorithms used.